<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-91e9c5c4=""><div class="content_outer_container" data-v-91e9c5c4=""><div class="share_preview_container" data-v-91e9c5c4=""><div class="dialog_list" data-v-91e9c5c4=""><div class="dialog_item" data-v-91e9c5c4=""><div class="dialog_question fir_dialog_question" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""><h1 class="fir_question_content" data-v-91e9c5c4="">
                                    How did Nuvectis Pharma's operating expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-91e9c5c4=""> <span class="user_desction" data-v-91e9c5c4="">
                                        
                                        5/8/2025 12:21am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-91e9c5c4="">Nuvectis Pharma's operating expenses for Q4 2024 are not currently available. However, the company's financial results for Q3 2024 indicate a decrease of approximately $2.0 million in operating expenses. This decrease partially offset the utilization of the at-the-market facility, resulting in a net loss of $4.2 million for the quarter. 

It's important to note that the information on Nuvectis Pharma's operating expenses for Q4 2024 is not currently available, so the trend of operating expenses in that quarter cannot be determined from the available data.</div> <div class="dialog_answer" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""> <div class="answer_robot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/AIme.ae832fb.png" alt="robot" class="avatar" data-v-91e9c5c4=""> <div class="user_name" data-v-91e9c5c4=""></div></div> <div class="question_content" data-v-91e9c5c4=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-4e97ba8a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-4e97ba8a=""> <div class="recommend-part" data-v-7790c618="" data-v-4e97ba8a=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:A,comeFrom:"AInvestShareLink",events:[],answerSource:n}],fetch:{},error:f,state:{sharePreviewModule:{loadJgySuccess:g,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:B,agent_id:a,output_media_info:[],task_id:a,language:a,source:n,cache_builder:a,reply_action:"Answer",execute_mode:s,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Nuvectis Pharma's operating expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Nuvectis Pharma's operating expenses trend in Q4 2024?\",\"user_id\":\"dp84922629\",\"user_name\":\"\",\"trace_id\":\"58a2993e-2001-4d7c-9039-46314ffb297d\",\"session_id\":\"58a2993e-2001-4d7c-9039-46314ffb297d\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:C,title:D,summary:E,full_summary:"Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers NXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “In the third quarter we continued to advance the development programs of NXP800 and NXP900. For NXP800, we anticipate the upcoming clinical data update from the Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer this month. In addition, we obtained a second Orphan Drug Designation for NXP800 from the FDA, for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.” Mr. Bentsur continued, “For NXP900, we have cleared 4 cohorts in the dose escalation Phase 1 study so far with no reports of dose limiting toxicities, and the dose escalation continues. In parallel, we are solidifying our plans for the next stage of development with both single agent and combination approaches to unlock the full therapeutic potential of NXP900, especially in non-small cell lung cancer in combination with currently approved targeted therapies to overcome acquired resistance to such therapies”. Mr. Bentsur concluded, “Finally, we continue to be responsible and efficient with our financial resources and believe that our current cash position will allow us to meet important milestones for both clinical programs and provide work",url:F,image_url:a,video_url:a,publish_time:G,search_extra_info:{search_burial_info:{id:t,uid:H,ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]}}},simhash:"b1651b07c75312eb",msg_id:t}}],answer_chain_name:L,agent_mode:M,native_answer:a,come_from:a,text_answer:A,trace_id:h,cost:13836,event_names:a,question:e,fallback_type:N,input_type:"typewrite",fall_back_reason:{fall_back_type:N,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:h,first_return_cost:2285,cache_type:"no_cache",question_id:h,transfer_question:e,signal_type:"ON_COMPLETE",start_time:u,remote_svc:n,slots:[],answer_type:s,user_id:v,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:h,session_id:h,user_id:v,question:e,source:n,raw_question:e,version:"3.4.1",action_name:w,nlu:{entity:[{type:O,value:"NVCT.O",market:P}]},output_time:u,deep_research:c,deep_thinking:c,agent_mode:M},extra:{}},{answer_path:i,section:{id:j,info_texts:["Thinking"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:i,section:{id:j,info_texts:["Querying Stock: NVCT Operating Expenses in Q4 2024"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:Q},logs:[],extra:{action:"Querying Stock",action_input:"NVCT Operating Expenses in Q4 2024",thought:"The user seeks to analyze Nuvectis Pharma's Q4 2024 operating expenses. I should focus on its Q4 2024 operating expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:d,section:{id:x,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:i,section:{id:j,info_texts:["Searching Web: Nuvectis Pharma Q4 2024 Operating Expenses"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:Q},logs:[],extra:{action:"Searching Web",action_input:"Nuvectis Pharma Q4 2024 Operating Expenses",thought:"I am unable to obtain Nuvectis Pharma's Q4 2024 operating expenses using FinQuery, now I will try again using Search."}},{answer_path:d,section:{id:x,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:x,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:i,section:{id:j,info_texts:["Generating Answer"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:"N",text_answer:R,rich_text:R,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:q,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:F,image_url:a,video_url:a,title:D,summary:E,index:C,publish_time:G,search_id:t,search_uid:H,search_ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:". This",text_answer:S,rich_text:S,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"NVCT",market_id:P,name:T,domain:O},pos:g,section_id:p,txt:T,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:" important",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:i,section:{id:j,info_texts:["Completed"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:l,query_text:l,trace_info:{item_id:"47fe8bca60baf65f8afe8965e48c3d9a",item_type:V,item_name:l,rec_info:W}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:g,type:"1",display2:c,url:a}},request_config:[{source_type:3,related_name:X}],puuid:y,tag:a,category:"custom",uuid:Y}],global:{urp_static_data:[{name:X,value:{status_code:g,columns:[{type:m,index_name:Z,key:Z},{type:m,index_name:_,key:_},{type:m,index_name:$,key:$},{type:m,index_name:aa,key:aa},{type:m,index_name:ab,key:ab}],datas:[{send_text:l,item_type:V,rec_info:W,display_text:l,rec_reason:a}],dataSize:B,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ac,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:r,"min-height":"100%",position:ad,height:r},isMaterial:c,id:ac,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:g,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:z,componentUuid:Y,script:[{name:ae,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:z,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:z},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:r,position:ad,height:r},isMaterial:b,_id:19,id:ae,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:af,voice_txt:a,tracking_info:{},uuid:y},order:{is_auto:c,render_for:af,chart_type:"command",puuid:y}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:w,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:s,answer_chain_name:L},is_deep_research:c,deep_thinking:c,create_time:1746678116805},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:f,docsData:[],quoteData:f},tplType:"question"},events:[],agentId:a}],userId:v,userName:a,startTime:u,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:f,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],traceTableData:f,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-nuvectis-pharmas-operating-expenses-trend-in-q4-2024-adf152\u002F",config:{_app:{basePath:ag,assetsPath:ag,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","How did Nuvectis Pharma's operating expenses trend in Q4 2024?",null,0,"58a2993e-2001-4d7c-9039-46314ffb297d","progress\u002Fsearching_for",1000,"searching_for","📊 How did Nuvectis Pharma's operating expenses compare to the previous quarter?","STR","ths_ainvest_lite_web","signal",2001,"rich_text","auto","agent","fc1cac74da27437d_1",1746678102969,"dp84922629","review stocks",999,"39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Nuvectis Pharma's operating expenses for Q4 2024 are not currently available. However, the company's financial results for Q3 2024 indicate a decrease of approximately $2.0 million in operating expenses. This decrease partially offset the utilization of the at-the-market facility, resulting in a net loss of $4.2 million for the quarter. \n\nIt's important to note that the information on Nuvectis Pharma's operating expenses for Q4 2024 is not currently available, so the trend of operating expenses in that quarter cannot be determined from the available data.",1,2,"Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights","The decrease of approximately $2.0 million was primarily a result of the operating expenses for the quarter, partially offset by the utilization of the at-the-market facility. The Company's net loss was $4.2 million for the three months ended September 30, 2024, compared to $5.9 million for the thre...","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2024\u002F11\u002F05\u002F2974797\u002F0\u002Fen\u002FNuvectis-Pharma-Inc-Reports-Third-Quarter-2024-Financial-Results-and-Business-Highlights.html","2024-11-05","fc1cac74da27437d","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","stock","186","thinking","Nuvectis Pharma's operating expenses for Q4 2024 are not currently available. However, the company's financial results for Q3 2024 indicate a decrease of approximately $2.0 million in operating expenses[^2]",". This decrease partially offset the utilization of the at-the-market facility, resulting in a net loss of $4.2 million for the quarter. \n\nIt's","Nuvectis Pharma"," important to note that the information on Nuvectis Pharma's operating expenses for Q4 2024 is not currently available, so the trend of operating expenses in that quarter cannot be determined from the available data.","llm_generated","2+679_496_21_554+0+0+58a2993e-2001-4d7c-9039-46314ffb297d+47fe8bca60baf65f8afe8965e48c3d9a+llm_generated+aimeTagAnalysis+0+0.023457882925868034+1","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/195837b.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/e402278.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7c15041.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/69a864a.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/9579193.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/6726d3c.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/c69ce63.js" defer=""></script>